Compound 27: Preclinical Data for a Novel MASH Drug Candidate

A study by Zhe Zhang reports preclinical data for a novel non-carboxylic steroidal FXR agonist, compound 27, designed for Metabolic dysfunction-associated steatohepatitis (MASH). The dataset, last updated in 2026, includes in vitro and in vivo efficacy and safety results from rat models. It is shared under a CC-BY-NC-4.0 license on figshare.

Use Cases

• Analyzing dose-response relationships based on EC50 values for FXR and TGR5 activity
• Comparing off-target receptor activation profiles based on MRGPRX4 data relative to OCA
• Evaluating oral bioavailability and pharmacokinetics based on the reported F value in rats
• Assessing in vivo efficacy for liver fibrosis and steatosis based on results from CCl4 and MASH models

Strengths

• Includes specific quantitative bioactivity metrics (e.g., FXR EC50 = 10 ± 3 nM)
• Reports key pharmacokinetic parameter (oral bioavailability F = 70.30% in rats)
• Provides in vivo efficacy results from two distinct animal models (CCl4 fibrosis and MASH)

Limitations

• Column-level documentation is absent; field semantics must be inferred after download
• Row count is unknown, which may limit suitability assessment
• Data may reflect experimental bias inherent to the specific preclinical study design

Provenance

Source

Zhe Zhang via figshare

Collection Method

Experimental data from rational drug design and preclinical animal studies.

Time Range

Study reported in 2026.

Freshness

Last updated 2026-05-08 19:06:38; freshness should be verified

Geography

Laboratory study; geographic origin of data is unknown.